Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Authors :: Keystone, E.
Emery, P.
Peterfy, C.G.
Tak, P.P.
Cohen, S.
Genovese, M.C.
Dougados, M.
Burmester, G.R.
Greenwald, M.
Kvien, T.K.
Williams, S.
Hagerty, D.
Cravets, M.W.
Shaw, T.
Source :: Annals of the Rheumatic Diseases. Feb, 2009, Vol. 68 Issue 2, p216, 6 p.
Publication Year :: 2009

Subjects :: Drug therapy -- Patient outcomes
Drug therapy -- Research
Rheumatoid arthritis -- Care and treatment
Rheumatoid arthritis -- Patient outcomes
Rheumatoid arthritis -- Research
Tumor necrosis factor -- Physiological aspects
Tumor necrosis factor -- Research
Health

Tools